And anti-CHI3L1 inhibitors and Kanamycin partially inhibit the infection of epithelial cells by these variant-of-concern (VOC) pseudo-viruses, once again proving that CHI3L1 is a common and VOC-independent therapeutic target in COVID-19. The gene discussed is CHI3L1; the disease is infection.